Abcuro

1 follower


Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class ant... Read more

Industries

Headquarters

Stage

Employees

Links

Org chart

Alex Martin

Collapse
Karen Tubridy
Chief Development Officer
H. Jeffrey Wilkins, MD
Chief Medical Officer
Janaki Subramanyam
VP, Head of Regulatory Affairs
Dave Borbas
Research VP, Head of Data Management
Garry Weems
VP, Clinical Science
Mike Gress
VP, Clinical Development & Head, Clinical Trial Management
Daniel Mansuri
Head, Corporate Development
Kristin Lurk
Senior Director, Program Management
LaDonna Hoffer
Senior Director, Operations
Donna Byrne
Director, Clinical Operations
Raquel Orozco
Director, CMC Manufacturing Operations
Terry Chaney
Associate Director, GMP QA Operations